Procrit | Erythropoietin Injection while Breastfeeding

Modern medicine has evolved so much so that sooner or later every breastfeeding mother needs to take it in one form or other. Medication that is present in mothers blood will transfer into her breast milk to some extent. Most drugs do so at low levels and pose no real risk to infants but then there are some exceptions. In This post will discuss whether Procrit | Erythropoietin Injection is safe in breast-feeding or not.

PROCRIT is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to -Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis (1.1). -Zidovudine in patients with HIV-infection (1.2). -The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy (1.3). Reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery (1.4). Limitations of Use PROCRIT has not been shown to improve quality of life, fatigue, or patient well-being (1.5). PROCRIT is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy (1.5). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure (1.5). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion (1.5). In patients scheduled for surgery who are willing to donate autologous blood (1.5). In patients undergoing cardiac or vascular surgery (1.5). As a substitute for RBC transfusions in patients who require immediate correction of anemia (1.5). 1.1 Anemia Due to Chronic Kidney Disease PROCRIT is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion. 1.2 Anemia Due to Zidovudine in Patients with HIV-infection PROCRIT is indicated for the treatment of anemia due to zidovudine administered at ≤ 4200 mg/week in patients with HIV-infection with endogenous serum erythropoietin levels of ≤ 500 mUnits/mL. 1.3 Anemia Due to Chemotherapy in Patients With Cancer PROCRIT is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. 1.4 Reduction of Allogeneic Red Blood Cell Transfusions in Patients Undergoing Elective, Noncardiac, Nonvascular Surgery PROCRIT is indicated to reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin > 10 to ≤ 13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. PROCRIT is not indicated for patients who are willing to donate autologous blood pre-operatively. 1.5 Limitations of Use PROCRIT has not been shown to improve quality of life, fatigue, or patient well-being. PROCRIT is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. In patients scheduled for surgery who are willing to donate autologous blood. In patients undergoing cardiac or vascular surgery. As a substitute for RBC transfusions in patients who require immediate correction of anemia.